Product & Service News

Stago Offers Three Factor VII Detection Methods

June 29, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that upon activation to its active form, factor VIIa (FVIIa) together with Tissue Factor (TF) comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin clot formation is critical for normal hemostasis to occur. All the methods below, which utilize citrated plasma, provide researchers with additional tools to investigate FVII biology, structure and function.

Stago Offers Three Procoagulant Microparticle Detection Methods

January 4, 2012, Parsippany, NJ, USA – Diagnostica Stago announces three new products to suit a variety of clinical research needs for procoagulant and total microparticle detection. Microparticles are tissue factor-bearing phospholipid vesicles that have often been the subject of clinical research studies into various conditions such as cancer, diabetes, sickle cell disorder, as well as parasitic and viral infections. Research into this topic is currently expanding rapidly, with many studies being communicated frequently at scientific meetings.

Diagnostica Stago, Inc. Introduces STA-Staclot DRVV Lupus Anticoagulant Assays

October 7, 2010, Parsippany, NJ, USA – Diagnostica Stago, Inc. is pleased to announce the addition of STA-Staclot DRVV Screen and STA Staclot DRVV Confirm lupus anticoagulant (LA) assays. These fully automated assays use the diluted Russell’s viper venom method to detect lupus anticoagulants in patient plasma, and each reagent is bar-coded for ease of use on Stago’s STA analyzers.